HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that demonstrated a 96% reduction in infection risk. The prestigious journal ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

The Food and Drug Administration has approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.. The drug will be ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to beat back the virus and prevent new infections.

FDA approves pricey new HIV prevention drug. The treatments will cost $14,000 a shot, and with numerous proposed major cuts to Medicaid and the Affordable Care Act in congress, funding for such ...

Why FDA approval of new HIV prevention drug is a big deal 02:25. The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

So this drug has generated enormous optimism in the HIV/AIDS community. But getting this drug to those who need it the most is not a sure thing. For more on this, we are joined by Mitchell Warren.

The drug is coming at a time when several studies aimed at finding an HIV cure or vaccine failed to yield expected results, even as the world races to end HIV/AIDs as a public health threat by 2030.